Findings are based on a systematic review and meta-analysis of 25 trials involving 26,478 patients with chronic kidney disease (CKD) with or without dialysis. Cardiovascular safety seems similar between hypoxia inducible factor prolyl hydroxylase inhibitors (HIF-PHI), erythropoiesis-stimulating agents (ESA).